Jul 192018
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, TX – Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Anthony G.=> Read full post

Aeglea BioTherapeutics appoints Board member and interim CEO Dr Anthony Quinn as CEO

From:: Aeglea BioTherapeutics appoints Board member and interim CEO Dr Anthony Quinn as CEO

Sorry, the comment form is closed at this time.

%d bloggers like this: